New brain cancer drug BRiTE enters first human safety trial
NCT ID NCT04903795
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This early-stage study tests a new drug called BRiTE for safety in 18 adults with a specific type of glioblastoma (a fast-growing brain cancer). The drug is given as a continuous IV drip over 4 days each month. Only patients whose tumors have a specific genetic marker (EGFRvIII) can join. The goal is to find a safe dose and see how the body handles the drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A simple lotion duo may shield skin from Tumor-Treating fields
- Can a modified herpes virus fight recurrent brain tumors?
- Can a new pill take on brain cancer?
- Can a special MRI reveal hidden brain tumors and guide a stronger radiation strike?
- Radioactive beads take aim at brain tumours
- Two-Drug combo aims to outsmart recurrent brain tumors